Antibodies against 4 Atypical Post-Translational Protein Modifications in Patients with Rheumatoid Arthritis
Lorena Rodríguez-Martínez,
Cristina Regueiro,
Sámer Amhaz-Escanlar,
Carmen Pena,
Paloma Herbello-Hermelo,
Antonio Moreda-Piñeiro,
Javier Rodriguez-Garcia,
Antonio Mera-Varela,
Eva Pérez-Pampín,
Antonio González
Affiliations
Lorena Rodríguez-Martínez
Experimental and Observational Rheumatology and Rheumatology Unit, Instituto de Investigacion Sanitaria-Hospital Clínico Universitario de Santiago (IDIS), 15706 Santiago de Compostela, Spain
Cristina Regueiro
Experimental and Observational Rheumatology and Rheumatology Unit, Instituto de Investigacion Sanitaria-Hospital Clínico Universitario de Santiago (IDIS), 15706 Santiago de Compostela, Spain
Sámer Amhaz-Escanlar
Department of Orthopedic Surgery and Traumatology, Instituto de Investigación Sanitaria-Hospital Clínico Universitario de Santiago (IDIS), 15706 Santiago de Compostela, Spain
Carmen Pena
Experimental and Observational Rheumatology and Rheumatology Unit, Instituto de Investigacion Sanitaria-Hospital Clínico Universitario de Santiago (IDIS), 15706 Santiago de Compostela, Spain
Paloma Herbello-Hermelo
Trace Element, Spectroscopy and Speciation Group (GETEE), Strategic Grouping in Materials (AEMAT), Department of Analytical Chemistry, Nutrition and Bromatology, Faculty of Chemistry, Universidade de Santiago de Compostela, 15782 Santiago de Compostela, Spain
Antonio Moreda-Piñeiro
Trace Element, Spectroscopy and Speciation Group (GETEE), Strategic Grouping in Materials (AEMAT), Department of Analytical Chemistry, Nutrition and Bromatology, Faculty of Chemistry, Universidade de Santiago de Compostela, 15782 Santiago de Compostela, Spain
Javier Rodriguez-Garcia
Department of Clinical Analysis, Instituto de Investigación Sanitaria-Hospital Clínico Universitario de Santiago (IDIS), 15706 Santiago de Compostela, Spain
Antonio Mera-Varela
Experimental and Observational Rheumatology and Rheumatology Unit, Instituto de Investigacion Sanitaria-Hospital Clínico Universitario de Santiago (IDIS), 15706 Santiago de Compostela, Spain
Eva Pérez-Pampín
Experimental and Observational Rheumatology and Rheumatology Unit, Instituto de Investigacion Sanitaria-Hospital Clínico Universitario de Santiago (IDIS), 15706 Santiago de Compostela, Spain
Antonio González
Experimental and Observational Rheumatology and Rheumatology Unit, Instituto de Investigacion Sanitaria-Hospital Clínico Universitario de Santiago (IDIS), 15706 Santiago de Compostela, Spain
Patients with rheumatoid arthritis (RA) show autoantibodies against post-translational protein modifications (PTMs), such as anti-citrullinated protein antibodies. However, the range of recognized PTMs is unknown. Here, we addressed four PTMs: chlorination, non-enzymatic glycation, nitration, and homocysteinylation, identified as targets of atypical RA autoantibodies in studies whose protocols we have followed. The modified antigens included collagen type II, an extract of synovial proteins and a selection of peptides. We interpreted the results according to the optical density (OD) obtained in an enzyme-linked immunosorbent assay ( ELISA) with the modified antigen and the corrected OD obtained after subtracting the reactivity against the unmodified antigen. The results showed evidence of specific antibodies against glycated collagen type II, as the corrected ODs were higher in the 182 patients with RA than in the 164 healthy controls (p = 0.0003). However, the relevance of these antibodies was doubtful because the magnitude of the specific signal was small (median OD = 0.072 vs. 0.027, respectively). There were no specific antibodies against any of the other three PTMs. Therefore, our results showed that the four PTMs are not inducing a significant autoantibody response in patients with RA. These results indicated that the repertoire of PTM autoantigens in RA is restricted.